Reanalysis of controversial meta-analysis says writing off rosiglitazone may be premature
User rating: not rated yet
Rosiglitazone, a drug marketed by GlaxoSmithKline as Avandia® for the treatment of type 2 diabetes, came under fire after an article published online May 21 by the New England Journal of Medicine linked it to significantly increased risk of heart attack and cardiovascular death.
Full story »
|

PhysOrg Forum
Video
Editorials
Free Magazines
Newsletter
Goto Archive
Suggest a story idea
Send feedback